Serum Müllerian Inhibiting Substance/Anti-Müllerian Hormone levels in patients with adult granulosa cell tumors directly correlate with aggregate tumor mass as determined by pathology or radiology

Henry L. Chang, Nima Pahlavan, Elkan F. Halpern, David T. MacLaughlin

Research output: Contribution to journalArticlepeer-review

Abstract

Objectives: Granulosa cell tumors (GCTs) comprise 2-5% of ovarian tumors. Serum Müllerian Inhibiting Substance (MIS, also known as anti-Müllerian hormone, or AMH) levels have been validated as a marker of GCT recurrence and progression. There has been little correlation between serum MIS/AMH levels and several clinical parameters in GCTs, including tumor burden. We have performed a retrospective review correlating aggregate tumor mass as reported by pathologic examination or by radiology with serum MIS/AMH levels drawn on the date of examination. Methods: We retrospectively identified 32 GCT patients at our institution over the last 15 years who had serum MIS/AMH measurements. Patients who had serum MIS/AMH measurements within three days of surgery or on the same day as abdominal computerized tomography scan (CT) or magnetic resonance imaging (MRI) were further evaluated. Results: We found a significant direct correlation between patient serum MIS/AMH levels and gross aggregate tumor mass determined by pathology (slope = 15.4 ± 6.06, r = 0.65, p < 0.04) or by radiographic aggregate tumor mass for all data points identified (slope = 0.07 ± 0.03, r = 0.33, p < 0.04) and after correcting for selection bias (slope = 1.45 ± 0.17, r = 0.93, p < 0.01). We also identified a significant difference between serum MIS/AMH levels between samples drawn the same day as negative and positive abdominal CT or MRI scans (8.16 ± 1.54 vs. 158.7 ± 32.2 ng/ml, p < 0.0001). Conclusions: These data indicate a significant direct correlation between serum MIS/AMH levels and both gross and radiographic aggregate tumor mass in GCT patients. Together with the current literature, the present data argue for a more prominent role for serum MIS/AMH in the management of GCTs.

Original languageEnglish (US)
Pages (from-to)57-60
Number of pages4
JournalGynecologic oncology
Volume114
Issue number1
DOIs
StatePublished - Jul 2009
Externally publishedYes

Keywords

  • Adult granulosa cell tumor
  • Anti-Müllerian hormone
  • Müllerian Inhibiting Substance
  • Ovarian sex-cord stromal tumor

ASJC Scopus subject areas

  • Oncology
  • Obstetrics and Gynecology

Fingerprint Dive into the research topics of 'Serum Müllerian Inhibiting Substance/Anti-Müllerian Hormone levels in patients with adult granulosa cell tumors directly correlate with aggregate tumor mass as determined by pathology or radiology'. Together they form a unique fingerprint.

Cite this